中国临床神经外科杂志2024,Vol.29Issue(7) :431-433.DOI:10.13798/j.issn.1009-153X.2024.07.010

中枢神经系统血管母细胞瘤的诊治进展

Progress in diagnosis and treatment of hemangioblastoma of the central nervous system

赵国杰 刘仁忠
中国临床神经外科杂志2024,Vol.29Issue(7) :431-433.DOI:10.13798/j.issn.1009-153X.2024.07.010

中枢神经系统血管母细胞瘤的诊治进展

Progress in diagnosis and treatment of hemangioblastoma of the central nervous system

赵国杰 1刘仁忠1
扫码查看

作者信息

  • 1. 430060武汉,武汉大学人民医院神经外科
  • 折叠

摘要

血管母细胞瘤是一种较为罕见的中枢神经系统良性肿瘤.它既可散发,亦可作为von Hippel-Lindau(VHL)病的一部分出现,约占颅内肿瘤的2%,占原发性脊髓肿瘤的2%~10%.影像学检查是术前诊断血管母细胞瘤的重要手段,而最终确诊需要依赖于病理诊断.目前,血管母细胞瘤的主要治疗方法为显微手术,病死率较低,远期手术效果良好.近年来,随着研究的深入,临床对于血管母细胞瘤有了新的认识.本文就中枢神经系统血管母细胞瘤的诊治进展作一综述,为临床诊治血管母细胞瘤提供参考.

Abstract

Hemangioblastoma is a relatively rare benign tumor of the central nervous system. It can occur sporadically or as part of von Hippel-Lindau (VHL) disease,accounting for approximately 2% of intracranial tumors and 2%~10% of primary spinal cord tumors. Imaging examinations are important means for preoperative diagnosis of hemangioblastoma,while the final diagnosis relies on pathological diagnosis. Currently,the main treatment for hemangioblastoma is microsurgery,which has a low mortality rate and favorable long-term surgical outcomes. In recent years,with in-depth research,there have been new insights into hemangioblastoma in clinical practice. This article presents a review of the progress in the diagnosis and treatment of hemangioblastoma of the central nervous system,providing a reference for the clinical diagnosis and treatment of hemangioblastoma.

关键词

血管母细胞瘤/中枢神经系统/von/Hippel-Lindau(VHL)病/诊断/治疗

Key words

Hemangioblastoma/Central nervous system/von Hippel-Lindau (VHL) disease/Diagnosis/Treatment

引用本文复制引用

出版年

2024
中国临床神经外科杂志
广州军区武汉总医院

中国临床神经外科杂志

CSTPCD
影响因子:0.781
ISSN:1009-153X
段落导航相关论文